These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26880400)

  • 1. Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors.
    Mukherjee S; Ma Z; Wheeler S; Sathanoori M; Coldren C; Prescott JL; Kozyr N; Bouzyk M; Correll M; Ho H; Chandra PK; Lennon PA
    Cancer Genet; 2016 Apr; 209(4):119-29. PubMed ID: 26880400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
    Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
    Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of copy number variant detection from panel-based next-generation sequencing data.
    Yao R; Yu T; Qing Y; Wang J; Shen Y
    Mol Genet Genomic Med; 2019 Jan; 7(1):e00513. PubMed ID: 30565893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
    Jour G; Scarborough JD; Jones RL; Loggers E; Pollack SM; Pritchard CC; Hoch BL
    Hum Pathol; 2014 Aug; 45(8):1563-71. PubMed ID: 24908143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations.
    Choi YJ; Choi JY; Kim JW; Lim AR; Lee Y; Chang WJ; Lee S; Sung JS; Chung HJ; Lee JW; Kang EJ; Kim JS; Lim T; Kim HS; Kim YJ; Ahn MS; Kim YS; Park JH; Lim S; Cho SS; Cho JH; Shin SW; Park KH; Kim YH
    Cancer Res Treat; 2022 Jan; 54(1):30-39. PubMed ID: 34015890
    [TBL] [Abstract][Full Text] [Related]  

    Belilovski Rozenblum A; Ilouze M; Dudnik E; Soussan-Gutman L; Dvir A; Peled N
    Harefuah; 2017 Nov; 156(11):686-691. PubMed ID: 29198084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy.
    Shen W; Szankasi P; Sederberg M; Schumacher J; Frizzell KA; Gee EP; Patel JL; South ST; Xu X; Kelley TW
    Br J Haematol; 2016 Apr; 173(1):49-58. PubMed ID: 26728869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
    Andersson C; Fagman H; Hansson M; Enlund F
    Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
    Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
    Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults.
    Ji J; Kaneva K; Hiemenz MC; Dhall G; Davidson TB; Erdreich-Epstein A; Hawes D; Hurth K; Margol AS; Mathew AJ; Robison NJ; Schmidt RJ; Tran HN; Judkins AR; Cotter JA; Biegel JA
    Neurooncol Adv; 2021; 3(1):vdab037. PubMed ID: 33948563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.
    D'Haene N; Le Mercier M; De Nève N; Blanchard O; Delaunoy M; El Housni H; Dessars B; Heimann P; Remmelink M; Demetter P; Tejpar S; Salmon I
    PLoS One; 2015; 10(9):e0138245. PubMed ID: 26366557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation Profiling of Clinically Advanced Cancers Using Next-Generation Sequencing for Targeted Therapy: A Lifespan Experience.
    Friedman K; Resnick MB; Safran H
    R I Med J (2013); 2015 Oct; 98(10):16-20. PubMed ID: 26422540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.
    Pugh TJ; Fink JM; Lu X; Mathew S; Murata-Collins J; Willem P; Fang M;
    Cancer Genet; 2018 Dec; 228-229():184-196. PubMed ID: 30393007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.
    Shen R; Seshan VE
    Nucleic Acids Res; 2016 Sep; 44(16):e131. PubMed ID: 27270079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.
    Zazo S; Pérez-Buira S; Carvajal N; Plaza-Sánchez J; Manso R; Pérez-González N; Dominguez C; Prieto-Potin I; Rubio J; Dómine M; Lozano V; Mohedano P; Carcedo D; Carias R; Rojo F
    Cancer Med; 2024 Feb; 13(3):e6827. PubMed ID: 38213074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients.
    Malapelle U; Vigliar E; Sgariglia R; Bellevicine C; Colarossi L; Vitale D; Pallante P; Troncone G
    J Clin Pathol; 2015 Jan; 68(1):64-8. PubMed ID: 25378536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.
    Shao D; Lin Y; Liu J; Wan L; Liu Z; Cheng S; Fei L; Deng R; Wang J; Chen X; Liu L; Gu X; Liang W; He P; Wang J; Ye M; He J
    Sci Rep; 2016 Mar; 6():22338. PubMed ID: 26936516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput detection of clinically targetable alterations using next-generation sequencing.
    Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
    Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing: A Solution for Transferring Integrated Pangenomic Studies into Routine Practice?
    Garinet S; Néou M; de La Villéon B; Faillot S; Sakat J; Da Fonseca JP; Jouinot A; Le Tourneau C; Kamal M; Luscap-Rondof W; Boeva V; Gaujoux S; Vidaud M; Pasmant E; Letourneur F; Bertherat J; Assié G
    J Mol Diagn; 2017 Sep; 19(5):776-787. PubMed ID: 28826610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.